Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Squamous NSCLC 1Colonic Neoplasms 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HLX07 × 1 year × Clear all
NCT07358585 2026-01-22

A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

Shanghai Henlius Biotech

Phase 1/2 Not yet recruiting
126 enrolled
Gastrointestinal

Colonic Neoplasms

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Henlius Biotech

Phase 2/3 Not yet recruiting
720 enrolled
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡